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Oncologic Outcomes and Predictive Factors for Recurrence 
Following Robot-Assisted Radical Cystectomy for Urothelial 
Carcinoma: Multicenter Study from Korea
The aim of our study was to evaluate intermediate-term oncologic outcomes, predictive 
factors for recurrence, and recurrence patterns in a multicenter series of patients treated 
with robot-assisted radical cystectomy (RARC) for urothelial carcinoma (UC) of the bladder. 
Between 2007 and 2015, 346 patients underwent RARC at multiple tertiary referral centers 
in Korea. Descriptive statistics were used for demographics and perioperative variables. 
Survival and recurrence were estimated with Kaplan-Meier analysis. Logistic regression 
models were used to determine predictors of recurrence. Median follow-up was 33 months 
(interquartile range [IQR], 7–50). The numbers of patients with organ-confined and lymph 
node (LN)-positive disease were 237 (68.4%) and 68 (19.7%), respectively. LN density (1–
20 vs. > 20) was 13.6% and 6.1%, with a median of 17 nodes removed (IQR, 9–23). In 
logistic regression analysis, type of LN dissection, and pathologic tumor stage were 
significant predictors of cancer recurrence and death from cancer. Local, distal recurrence 
and secondary UC occurred in 7 (2.0%), 53 (15.3%), and 4 (1.2%) patients, respectively. 
The 5-year overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival 
(RFS) were 78%, 84%, and 73%, respectively. At last follow-up, RFS for extended pelvic 
LN dissection vs. standard pelvic LN dissection was 70% and 47% (P = 0.038). In addition, 
at last follow-up, LN density (0 vs. 1–20 vs. over 20) was 67%, 41%, and 29%, 
respectively (P < 0.001). Patients undergoing RARC in this multi-institutional cohort 
demonstrated intermediate-term oncologic outcomes, predictive factors for recurrence, 
and recurrence patterns that were not unusual.
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INTRODUCTION
Approximately 20% to 30% of patients will present with muscle-
invasive bladder cancer (MIBC) at the time of initial diagnosis. 
Because this is one of the most aggressive epithelial tumors, a 
significant proportion of patients will experience recurrence, 
and approximately 50% of cystectomy patients will ultimately 
die of disease despite therapy (1). Radical cystectomy (RC) with 
bilateral pelvic lymph node dissection (PLND) is the treatment 
of choice for clinically localized MIBC and has also been per-
formed for patients with aggressive non-MIBC (NMIBC). Nev-
ertheless, this procedure still has a 50% 2-year risk of distant me-
tastasis and a 60% 5-year risk of death in patients with MIBC (2).
 Robot-assisted radical cystectomy (RARC) has been emerg-
ing as an equivalent approach to open RC with potentially equiv-
alent oncological outcomes (3). Moreover, it has been suggest-
ed that RARC results in improvements in perioperative morbid-
ity and ease of recovery, as well as permitting earlier initiation 
of adjuvant systemic therapies (4,5). However, despite these 
potential perioperative benefits (6), RARC has been criticized 
for the paucity of reports regarding long-term oncologic out-
comes (7). Despite the fact that early oncologic outcomes ap-
pear to be favorable, longer-term follow-up studies are still lack-
ing (8,9).
 In this multicenter study, we analyzed intermediate-term 
oncologic outcomes following RARC with bilateral PLND in 346 
patients with bladder cancer (BC). In addition, we analyzed pre-
dictive risk factors and patterns of recurrence in comparison to 
the findings of previous studies. 
MATERIALS AND METHODS
After approval was obtained from the Institutional Review Board 
at each center, we retrospectively reviewed patient databases. 
We identified 346 patients treated with RARC between 2007 and 
2015 at six institutions in Korea.
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 Study participants included patients with recurrent/multiple 
or high-grade superficial or MIBC without evidence of meta-
static disease on preoperative imaging (10). High-grade super-
ficial BC was defined as pT1G3 tumors, and recurrent BC was 
defined as pTaG1G2 BC that had recurred despite three or more 
transurethral resections. The criteria also include bacillus Cal-
mette-Guérin refractory tumors, defined according to the Euro-
pean Association of Urology guidelines (11). Eligible patients 
were medically cleared for RC with PLND, aged ≥ 18 years, and 
had clinical stage Ta–T4/N0–N3/M0 BC. Exclusion criteria in-
cluded clinical stage M1, any contraindication to the Trendelen-
burg position, or prior “extensive” abdominal surgery.
 The surgical technique of RARC with bilateral PNLD and uri-
nary diversion (UD) has been previously described (12). Stan-
dard PNLD was most commonly used in patients included in 
the current study; this technique consists of excising lymphatic 
tissue from the external iliac artery, external iliac vein, obtura-
tor nerve, and hypogastric artery up to the common iliac artery. 
Extended PLND includes standard PLND in addition to resec-
tion of tissue medial to the genitofemoral nerve and along the 
common iliac artery up to the aortic bifurcation. UD was per-
formed mostly extracorporeally in the current study population, 
and was performed intracorporeally in 53 (15.3%) subjects.
 The endpoint of the present study was the identification of 
predictive factors for recurrence and recurrence patterns. Lo-
gistic regression was performed for analysis of variables to iden-
tify predictive factors for recurrence. Potential predictors includ-
ed diversion technique (ileal conduit vs. orthotopic bladder 
substitution [OBS]), corporeal type (extracorporeal vs. intracor-
poreal), mean time to Foley removal, mean hospital stay, surgi-
cal margins, type of PLND (extended vs. standard), lymph node 
(LN) yield, pathologic tumor stage, and nodal stage. Tumor grade 
and pathologic stage were determined using the 2002 Ameri-
can Joint Committee on Cancer tumor, node, and metastasis 
(TNM) staging system and the 2004 World Health Organization/ 
International Society of Urologic Pathologists classification of 
papillary urothelial neoplasms, respectively (13).
 Additional endpoints included overall survival (OS), cancer-
specific survival (CSS), and recurrence-free survival (RFS). OS 
was defined as the time from date of cystectomy to death due to 
any cause. CSS was defined as the time to death due to BC, wher-
eas RFS was defined as the time from date of cystectomy to lo-
cal or metastatic recurrence, based on histologic or radiologic 
evidence. The estimated distributions of OS, CSS, and RFS were 
obtained using Kaplan-Meier analysis. The log-rank test was 
used to compare the Kaplan-Meier curves among pathologic 
tumor stage, type of LN dissection, LN density, and margin sta-
tus. All analyses were performed using SPSS software (version 
20.0; SPSS Inc., Chicago, IL, USA). P values < 0.05 were consid-
ered statistically significant.
Ethics statement
This study conformed to the standards of the Declaration of 
Helsinki and current ethical guidelines. The study protocol was 
reviewed and approved by the Institutional Review Board of 
Korea University Anam Hospital (ED10120). Informed consent 
was waived by the board.
RESULTS
Baseline data
Basic characteristics of patients and perioperative outcomes 
are shown in Table 1. The mean age of patients was 65.7 ± 10.6 
years (interquartile range [IQR], 60.0–73.0). Among the patients, 
296 (85.5%) were men, and 36 (10.4%) received neoadjuvant 
chemotherapy. The types of UD included ileal conduit (38.4%), 
OBS (57.2%), and continent cutaneous urinary diversion (CCUD; 
4.3%). Diversion types included extracorporeal (80.3%), intra-
corporeal (15.3%), and CCUD (4.4%). The numbers of patients 
who underwent standard PLND and extended PLND were 179 
Table 1. Baseline characteristics of patients and perioperative parameters 
Baseline characteristics Values (n = 346) IQR
Age, yr 65.7 ± 10.6 60.0–73.0
Gender -
   Male 296 (85.5)
   Female 50 (14.5)
BMI, kg/m2 21.8 ± 3.0 21.9–25.9
ASA score ≥ 3 12 (3.5) -
Previous abdominal surgery 54 (15.6) -
Preoperative chemotherapy 36 (10.4) -
Type of UD -
   Ileal conduit 133 (38.4)
   OBS 198 (57.2)
   CCUD 15 (4.3)
Diversion technique -
   Extracorporeal 278 (80.3)
   Intracorporeal 53 (15.3)
   CCUD 15 (4.4)
Type of PLND -
   Standard PLND 179 (51.7)
   Extended PLND 167 (48.3)
Perioperative outcomes
Mean operation time, min 519.3 ± 153.5 410.5–603.8
Mean console time, min 325.5 ± 135.1 222.7–395.0
Mean EBL, mL 571.8 ± 525.0 221.2–723.0
   Mean surgical transfusion 259.1 ± 469.7 0–400
   Mean postsurgical transfusion 150.4 ± 319.0 0–200
Mean time to flatus, hr 82.8 ± 35.6 60.1–96.0
Mean time to oral intake, day 5.1 ± 2.3 4.0–6.0
Mean time to Foley removal, day 16.7 ± 18.7 6.0–22.0
Mean hospital days, day 21.4 ± 12.4 13.0–26.8
Values are presented as number (%) or mean ± SD.
IQR = interquartile range, BMI = body mass index, ASA = American Society of Anes-
thesiologists, UD = urinary diversion, OBS = orthotopic bladder substitution, CCUD =  
continent cutaneous urinary diversion, PLND = pelvic lymph node dissection, EBL =  
estimated blood loss, SD = standard deviation.
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(51.7%) and 167 (48.3%), respectively.
Oncologic outcomes
The number of patients with high tumor grade was 269 (77.7%), 
and 237 (68.4%) patients had organ-confined disease. Rates of 
LN density (1–20 vs. > 20) were 13.6% and 6.1%, respectively, 
while 278 patients (80.3%) had node-negative disease. LN yield 
was 17.1 ± 12.0 (IQR, 9–23), which included yields of 10.7 ± 12.0 
and 24.0 ± 11.9 in standard and extended PLND, respectively. 
Nine patients (2.6%) had positive surgical margins (PSMs) (T1/
T2: 1.2%; T3/T4: 1.4%) (Table 2).
Predictive factors and patterns of recurrence
In logistic regression analysis, the type of LN dissection was a 
significant predictor of recurrence and death from cancer (odds 
ratio [OR], 2.816; 95% confidence interval [CI], 1.27–6.20; P < 0.001 
and OR, 5.953; 95% CI, 2.25–15.65; P = 0.001, respectively), as 
was pathologic tumor stage (OR, 2.417; 95% CI, 1.36–4.30; P =  
0.003 and OR, 3.804; 95% CI, 1.80–8.05; P < 0.001, respectively). 
PSM (OR, 10.916; 95% CI, 1.90–62.57; P = 0.007), LN yield (OR, 
0.946; 95% CI, 0.91–0.99; P = 0.010), and positive LN (OR, 1.087; 
95% CI, 1.01–1.17; P = 0.026) showed statistical significance for 
cancer recurrence, while corporeal type did not show signifi-
cance (P = 0.056) (Table 3).
 Local and distant recurrence occurred in 7 (2.0%) and 53 
(15.3%) patients, respectively. Regarding local recurrence, 6 pa-
tients experienced recurrence on the cystectomy bed, while 
only 1 patient experienced recurrence on the PLND template. 
In terms of distant recurrence, the lung (15/53) was the single 
most common site, followed by extrapelvic LN (13/53), bone 
(7/53), and the liver (4/53). Nine patients had multiple recur-
rence sites (9/53). Another 4 patients experienced recurrence 
of secondary urothelial carcinoma (UC) in the upper urinary 
tract (2 patients) and urethra (2 patients). The distribution of 
recurrence locations is shown in Fig. 1.
Kaplan-Meier curves for OS, CSS, and RFS
The Kaplan-Meier curves show the OS, CSS, and RFS. The 5-year 
OS, CSS, and RFS rates were 78%, 84%, and 73%, respectively 
(Fig. 2). We analyzed RFS at the last follow-up according to sev-
eral factors to determine their effect on recurrence. In the pres-
ent study, the presence of non-organ confined disease (> pT2) 
was a significant predictor of RFS (organ-confined vs. non-or-
gan-confined: 68% and 51%; log-rank test: P < 0.001; Fig. 3A). 
At the last follow-up, RFS for extended PLND vs. standard PLND 
was 70% and 47%, respectively (P = 0.038; Fig. 3B). At the time 
Table 2. Pathologic outcomes 
Pathologic outcomes Value (n = 346) IQR
Histologic type
   UC 346 (100.0) -
Pathologic tumor stage -
   T0/Ta/Tis 53 (15.3)
   T1/T2 184 (53.1)
   T3/T4 109 (31.6)
Soft tissue margin positive 9 (2.6) -
   T1/T2 4 (1.2)
   T3/T4 5 (1.4)
LN yield 17.1 ± 12.0 9.0–23.0
   Standard PLND 10.7 ± 12.0
   Extended PLND 24.0 ± 11.9
No. of patients with LN positive, % 68 (19.7)
LN density, % 25.5 ± 27.1 7.1–41.9
   Node negative 278 (80.3)
   Node density 1%–20% 47 (13.6)
   Node density >  20% 21 (6.1)
Pathologic nodal stage -
   N0 278 (80.3)
   N1/N2/N3 68 (19.7)
Follow-up, mon 32.9 ± 25.4 7.0–50.3
Values are presented as number (%) or mean ± SD.
IQR = interquartile range, UC = urothelial carcinoma, LN = lymph node, PLND = pelvic 
lymph node dissection, SD = standard deviation. 
Table 3. Logistic regression analysis of variables associated with recurrence and death from BC after treatment with RARC
Variables
Cancer recurrence Death from BC
OR 95% CI P value OR 95% CI P value
Corporeal type
   Extracorporeal vs. intracorporeal 0.301 0.09–1.03 0.056 0.316 0.08–1.19 0.089
PSMs 10.916 1.90–62.57 0.007* 1.844 0.29–11.60 0.514
Type of PLND
   Extended vs. standard 2.816 1.27–6.20 0.010* 5.935 2.25–15.65 0.000†
No. of removed LN 0.946 0.91–0.99 0.010* 0.993 0.94–1.04 0.776
No. of positive LN 1.087 1.01–1.17 0.026* 1.042 0.93–1.17 0.484
Pathologic tumor stage
   pT2 or less vs. pT3 or pT4 2.417 1.36–4.30 0.003* 3.804 1.80–8.05 0.000†
Nodal stage
   N0 vs. N1/N2/N3 1.027 0.39–2.71 0.957 1.019 0.31–3.39 0.976
BC = bladder cancer, RARC = robot-assisted radical cystectomy, OR = odds ratio, CI = confidence interval, PSM = positive surgical margin, PLND = pelvic lymph node dissec-
tion, LN = lymph node.
*P < 0.050; †P < 0.010.
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of last follow-up, LN density (0 vs. 1–20 vs. over 20) was 67%, 
41%, and 29%, respectively (P < 0.001; Fig. 3C). Furthermore, a 
PSM was associated with a significantly increased risk of dis-
ease recurrence compared to a negative surgical margin (64% 
and not calculable, respectively; P < 0.001; Fig. 3D).
DISCUSSION
In our study, analysis of oncologic outcomes in intermediate 
term follow-up was the primary endpoint. The results of our 
multicenter trial demonstrated similar oncologic results and 
predictive factors for recurrence compared with other studies. 
The 3- and 5-year OS, CSS, and RFS were slightly higher than 
those found in contemporary RARC series. Pathologic tumor 
stage, extent of PLND, LN density, and PSM were significant 
prognostic factors with regard to RFS.
 We analyzed predictive risk factors for recurrence in compar-
ison to previous studies. It is known that LN status is the most 
powerful surrogate prognostic marker for long-term RFS and 
OS following RC (14). In the present study, a median of 17 LNs 
were removed (IQR, 9–23). There is no general consensus in the 
literature regarding the exact threshold of nodes at which a sur-
vival benefit can be predicted, with most studies reporting num-
bers in the range of 9 to 16 (14).
 In terms of PLND extent, the current study did not reveal un-
usual results compared to those of previous studies. One criti-
cism of RARC is that the extended PLND cannot be as complete 
as that in open RC due to limitations in accessing the nodes at 
the aortic bifurcation. However, recent RARC series reveal LN 
yields comparable to those observed in open RC series (15,16). 
In the current study, compared with standard PLND, extended 
PLND resulted in significantly reduced risk of recurrence and 
death from BC (P = 0.001 and P < 0.001, respectively). In addi-
tion, at the last follow-up, there was a significant difference in 
RFS for extended PLND vs. standard PLND (P = 0.038). PLND 
is considered an integral part of RC and there are some evidenc-
es that the greater number of nodes removed during RC, the 
better the chance of long-term survival (17). A few studies have 
argued that this finding is the result of a Will Rogers phenome-
non, an apparent paradox obtained from moving cases from 
the pN0 to the pN+ group, which might account for the better 
results observed with extended PLND. However, one important 
reason for performing extended PLND is that, although “skip” 
metastasis appears to be a relatively rare event in BC, cases have 
been reported in the literature (18). This means that the obtura-
tor fossa is not necessarily the first site of BC metastasis. In ad-
dition, several previous studies have reported a survival benefit 
with extended PLND or in accordance with increasing numbers 
of removed LNs (19,20).
 Another prognostic factor for RFS observed in our study was 
LN density (P < 0.001). LN density refers to the number of LNs 
containing metastatic deposits divided by the total number of 
nodes removed. Several studies have suggested that LN density 
could have prognostic value, and some studies have suggested 
that LN density is superior to the TNM classification system, as 
well as to the absolute number of positive LNs, in predicting OS 
and CSS (21). In addition, a recent meta-analysis showed that 
LN density could be an independent predictor of clinical out-
comes in LN-positive patients (22).
 Margin status is also an important prognostic factor for RFS 
Fig. 1. Distribution of locations among patients with recurrence after RARC.
RARC = robot-assisted radical cystectomy, PLND = pelvic lymph node dissection.
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OS = overall survival, CSS = cancer-specific survival, RFS = recurrence-free survival.
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following RC (23). A PSM was associated with a significantly in-
creased risk of disease recurrence. In the present study, 9 pati-
ents (2.6%) had PSMs, similar to the findings of a previous study 
(24). Furthermore, a PSM was associated with a significantly 
increased risk of disease recurrence compared to a negative sur-
gical margin (P = 0.007).
 Meanwhile, with emerging surgical techniques, continued 
assessments are necessary to ensure optimization of outcomes. 
Some authors have reported that there could be a distinct pat-
tern of recurrence following RARC. Nguyen et al. (25) reported 
that extrapelvic LN locations and peritoneal carcinomatosis 
were more frequent following RARC than open RC in patients 
with distant recurrence. This is a matter for consideration, since 
recurrence patterns of cancer could have a great effect on pa-
tient survival. Therefore, another aim of this study was to deter-
mine whether or not recurrence patterns were unusual in pa-
tients undergoing RARC with PLND.
 Regarding distant recurrence in solid organs, the lung, bone, 
and liver remained the most frequent sites, a finding consistent 
with previous studies (26). The recurrence of extrapelvic LN me-
tastasis (3.8%) was similar to that observed in previous open RC 
series (3,25). However, in the present study, some cases of ex-
trapelvic LN recurrence were concentrated in the initial period 
following the performance of RARC, which could be a reason 
for the relatively higher rates of distant recurrence. Another con-
cern regarding RARC was the higher rate of peritoneal carcino-
Fig. 3. Kaplan-Meier curves for oncologic outcome. (A) RFS at last follow-up for organ-confined vs. non-organ-confined disease was 68% vs. 51%, respectively (P < 0.001); (B) 
RFS at last follow-up for extended and standard PLND was 70% vs. 47%, respectively (P = 0.038); (C) RFS at last follow-up between LN density was 67%, 41%, and 29%, re-
spectively (P < 0.001); and (D) RFS at last follow-up for negative vs. positive soft tissue margin status was 64% vs. not calculable, respectively (P < 0.001).
RFS = recurrence-free survival, PLND = pelvic lymph node dissection, LN = lymph node.
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matosis, which implies cancer cell dispersal by pneumoperito-
neum. In the current study, no recurrence of peritoneal carci-
nomatosis was observed. We investigated the recurrence of sec-
ondary UC separately. This is important because the follow-up 
strategy should reflect the risk or extravesical recurrence (in par-
ticular, the prostatic urethra in men, as well as the upper urinary 
tract) (27). This result did not show a significant difference com-
pared with the findings of previous studies (25).
 In the present study, 5-year OS, CSS, and RFS were 78%, 84%, 
and 73%. In a small set of patients who received more than 5 
years of follow-up, patients undergoing RARC experienced an 
OS of 64%, CSS of 75%, and RFS of 50% (8). A series of 121 pa-
tients who underwent RARC provides additional longer follow-
up data, with a median follow-up of 5.5 years. In this study, the 
OS, CSS, and RFS were 48%, 71%, and 65% at 5 years, and 35%, 
63%, and 54% at 10 years (28). The survival results obtained in 
the current study suggest that the enrolled patients had more 
favorable oncologic outcomes compared with previously report-
ed RARC series. In fact, the rate of organ-confined disease ac-
cording to pathologic results was relatively higher in compari-
son to other studies from high-volume centers. We adduced 
oncologic comparative data in Table 4.
 There are several limitations to our study, foremost the limi-
tations inherent to retrospective analyses. Therefore, our study 
is limited by biases such as lack of random assignment, patient 
selection, and incomplete data acquisition. It should also be 
noted that the present findings apply to patients treated by an 
experienced surgeon, at a high-volume tertiary care center. This 
may limit the generalizability of these findings to low-volume 
community-based practices. In addition, the patients in this 
study underwent RC performed by multiple surgeons and had 
specimens evaluated by multiple pathologists. However, all sur-
geons operated at selected centers with significant experience 
in BC management, which might increase the external validity 
of the data compared to the single center, single surgeon setting.
 In conclusion, we found that oncologic outcomes and pre-
dictive factors for recurrence were not unusual in intermediate-
term follow-up among patients who underwent RARC. In addi-
tion, there were no significant differences in recurrence patterns 
compared with open RC. Further validation would be warrant-
ed to better understand the oncologic outcomes of RARC for UC.
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